BACKGROUND. Chemotherapy for metastatic breast cancer is palliative, and the optimal duration of therapy is unknown. We designed a trial to determine whether continuous treatment is superior to stopping treatment after a brief induction period and resuming treatment when the disease progresses. METHODS. We treated 250 women with metastatic breast cancer with six courses of cyclophosphamide, doxorubicin, and fluorouracil given every three weeks. At the completion of this induction period, women whose disease either regressed or remained stable were randomly assigned to receive either continued treatment with cyclophosphamide, methotrexate, and fluorouracil (maintenance therapy) or no further treatment (observation) followed by treatment with cyclophosphamide, methotrexate, and fluorouracil when disease progression became evident (reinduction). RESULTS. The combined rate of complete and partial responses after initial therapy was 30 percent (71 of 233 patients who could be evaluated; 95 percent confidence interval, 25 percent to 37 percent). In another 42 percent (98 patients), the disease remained stable. A total of 145 patients were randomized. Seventy-one were randomly assigned to the maintenance-therapy group, and 74 to the observation group. The median time to progression was 9.4 months for patients in the maintenance-therapy group and 3.2 months for patients in the observation group (P less than 0.001). After reinduction therapy, the median time to progression was 3.5 months. The median length of survival from the time of initial therapy was 14.8 months for all 250 patients; it was 21.1 months for the 71 patients in the maintenance-therapy group and 19.6 months for the 74 patients in the observation group (P = 0.67). Maintenance therapy was the most important determinant of the time before progression (P less than 0.001), but it was not associated with prolonged survival. The changes in performance status were similar in the patients in both groups, but nausea, vomiting, and mucositis were significantly more frequent in the maintenance-therapy group. CONCLUSIONS. In patients with breast cancer who received induction chemotherapy for 18 weeks, subsequent continuous chemotherapy was associated with a significant prolongation of the time before progression as compared with those receiving no further therapy; overall survival, however, was not significantly different in the two groups.
Source Information
Comprehensive Cancer Center, Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27103.
This article has been cited by other articles:
Stupp, R., Hegi, M. E., Gilbert, M. R., Chakravarti, A.
(2007). Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. JCO
25: 4127-4136
[Abstract][Full Text]
Gennari, A., Amadori, D., De Lena, M., Nanni, O., Bruzzi, P., Lorusso, V., Manzione, L., Conte, P. F.
(2006). Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. JCO
24: 3912-3918
[Abstract][Full Text]
Sparano, J. A., Bernardo, P., Stephenson, P., Gradishar, W. J., Ingle, J. N., Zucker, S., Davidson, N. E.
(2004). Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. JCO
22: 4683-4690
[Abstract][Full Text]
Dagher, R., Johnson, J., Williams, G., Keegan, P., Pazdur, R.
(2004). Accelerated Approval of Oncology Products: A Decade of Experience. JNCI J Natl Cancer Inst
96: 1500-1509
[Abstract][Full Text]
Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., Kabbaj, O., Spano, J. P., Marsiglia, H., Rouzier, R., Delaloge, S., Spielmann, M.
(2004). Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. JCO
22: 3302-3308
[Abstract][Full Text]
Lal, R., Dickson, J., Cunningham, D., Chau, I., Norman, A. R., Ross, P. J., Topham, C., Middleton, G., Hill, M., Oates, J.
(2004). A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor--Resistant Advanced Colorectal Cancer. JCO
22: 3023-3031
[Abstract][Full Text]
Cannistra, S. A.
(2004). The Ethics of Early Stopping Rules: Who Is Protecting Whom?. JCO
22: 1542-1545
[Full Text]
Ozols, R. F.
(2003). Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical Benefit. JCO
21: 2451-2453
[Full Text]
Olivotto, I. A., Chua, B., Allan, S. J., Speers, C. H., Chia, S., Ragaz, J.
(2003). Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer. JCO
21: 851-854
[Abstract][Full Text]
Cardoso, F., Di Leo, A., Lohrisch, C., Bernard, C., Ferreira, F., Piccart, M. J.
(2002). Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol
13: 197-207
[Abstract][Full Text]
Del Mastro, L., Venturini, M., Lionetto, R., Carnino, F., Guarneri, D., Gallo, L., Contu, A., Pronzato, P., Vesentini, L., Bergaglio, M., Comis, S., Rosso, R.
(2001). Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. JCO
19: 2213-2221
[Abstract][Full Text]
(2000). Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment. JCO
18: 3115-3124
[Abstract][Full Text]
Norris, B., Pritchard, K. I., James, K., Myles, J., Bennett, K., Marlin, S., Skillings, J., Findlay, B., Vandenberg, T., Goss, P., Latreille, J., Rudinskas, L., Lofters, W., Trudeau, M., Osoba, D., Rodgers, A.
(2000). Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. JCO
18: 2385-2394
[Abstract][Full Text]
Chan, S., Friedrichs, K., Noel, D., Pinter, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., Yelle, L., von Minckwitz, G., Korec, S., Simmonds, P., Buzzi, F., Gonzalez Mancha, R., Richardson, G., Walpole, E., Ronzoni, M., Murawsky, M., Alakl, M., Riva, A., Crown, J.
(1999). Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer. JCO
17: 2341-2341
[Abstract][Full Text]
Ellison, N. M.
(1998). Palliative chemotherapy. AM J HOSP PALLIAT CARE
15: 93-103
Kearsley, J. H
(1994). Some basic guidelines in the use of chemotherapy for patients with incurable malignancy. Palliat Med
8: 11-17
[Abstract]
Previous
